Medlab Clinical Limited (ASX: MDC) is a medical research and development company based in Australia. It is researching and formulating novel bio-therapeutic drugs for treatment of early to moderate stage chronic diseases.
According to the National Center for Health Statistics, US any disease that lasts for more than three months is called chronic disease. The example of such chronic diseases are Asthma, Diabetes, Arthritis etc. Medlab has been working on 5 core research programs, at different phases of investigation. The researches of the company believe that it is at the frontline of fresh bio-therapeutic discoveries, which can bridge the unmet needs in the ever-increasing global trends in chronic diseases. Currently, the company is focusing on delivering new medicines for Obesity management, Anti-aging, Chronic Kidney Disease etc.
On 14th March 2019, the company announced encouraging results from both clinical trial and approved Government Special Access Scheme’s (SAS) use of NanaBis. Medlab’s CEO, Dr Sean Hall described various key aspects of NanaBis to Medical Practitioners as part of an on-going medical education which consisted of:
Beyond the Stage 1 Advanced Cancer Pain Trial Results
After the previously announced Stage 1 results of the drug NanaBis, data was collected from that trial and was directly compared to published data for an ARTG approved Cannabis Drug. The results witnessed similar plasma level of THC and CBD with NanaBis comprising half of the dose and it was also noted, that the rate of absorption for NanaBis was faster.
NanaBis Case Studies
There were several case studies for NanaBis discussed under SAS, some of them are mentioned below:
- The Patient 1 with severe chronic pain was taking 5 medications prior to NanaBis namely: Diazepam, Pregablin, Meloxicam, Oxycodone and Tramadol. Post being on NanaBis medication, the patient Ceased all other medications after 1 month. The rating of the pain level came down to 2/10 from previously mentioned pain level of 9/10.
- Patient 2 with severe chronic back pain was also taking 6 medications prior to NanaBis namely: Tapentadol, Pregablin, Meloxicam, Oxycodone, Panadeine Forte and Tramadol. Post being on NanaBis medication, the patient significantly reduced other medications after 2 weeks. The rating of the pain level reduced to 4/10 from previously mentioned pain, touching the maximum level of 10/10.
- The Patient 3 with chronic pain was taking only 1 medication prior to NanaBis named as Mersyndol. Post being on NanaBis medication, there was a significant reduction in opioids post 10 days. Patients reported better quality of sleep post being on NanaBis medication.
The results of entire case studies assembled by SAS had some commonly witnessed results which are as follows:
- Significant improvements were witnessed by the patients in terms of overall quality of life, inclusive of sleep and movement with reduced pain.
- Reduction of prior prescribed medication was noticeable.
- Every patient mentioned a reduction in pain severity scores.
Based on the activities during the trial, the company is actively pursuing regulatory pathways for the European Medicines Agency (EMA), Federal Drug Administration (FDA) in USA and Therapeutic Goods Association (TGA) in Australia.
On 5th March 2019, the company announced that it had signed HoA with Pharmascience Inc for NanaBis.
The stock of the company, by the end of the trading session was 3.75% down and stood at A$0.385 on ASX as of 14th March 2019 compared to the previous closing of A$0.4. The stock has fallen more than 44% in the last one year.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.